NuScale Power Stock Is Cheap, but Does That Make It a Buy Now?

NuScale Power shares have fallen 75% from their 52-week high as the company still lacks its first reactor sale. The article says the SMR technology is regulatory-approved and supported by U.S. government funding, but commercialization remains unproven and the stock is still considered risky. AI-driven power demand is presented as a potential long-run tailwind, but investors are urged to wait for an actual sale before buying.

Analysis

SMR is a classic “future optionality, current zero” setup: the market is still assigning value to a manufacturing platform before it has proven repeatability, installation cadence, or financingability. In these stories, the first commercial sale is not just a revenue event; it is a validation event that can re-rate the equity by multiple turns if it comes with a credible backlog and a clear path to serial deployment. Until that happens, the stock will likely trade more like a financing-sensitive biotech than a utility-adjacent industrial, with sentiment and capital markets access driving the tape more than fundamentals.

The second-order issue is that the competitive landscape may be improving faster than NuScale’s conversion rate. Policy support for SMRs helps the entire category, but it also lowers the barrier for alternative designs, larger incumbents, and utility partners to shop around for better economics once procurement starts to matter. If power demand from AI sustains, the winner may be the solution that can scale fastest and cheapest, not necessarily the first approved design; that creates a real risk that SMR becomes a category story while NuScale remains a single-name execution story.

The drawdown likely reflects rational de-risking rather than a broken thesis. Near term, the biggest catalyst is not “more interest” but an actual contract, financing package, or manufacturing milestone that de-risks delivery timing; absent that, the stock can stay cheap for months. The contrarian angle is that the market may be underpricing how quickly a first order can change the equity story, but it is also underestimating how much dilution and project delay can occur before that inflection arrives.

Key Decisions for Investors

• Avoid outright longs in SMR until a signed first sale is announced; if you want exposure, wait for confirmation because the setup is binary and execution risk dominates over a 3-6 month horizon.
• For tactical upside, consider a small SMR call spread 3-6 months out only on a signed-contract headline; risk/reward improves materially if the market reprices from 'unproven' to 'order book forming.'
• If already long SMR, trim into any contract rumor strength and keep a hard risk limit; the stock can re-rate sharply on validation but can just as easily fade on financing or delivery slippage.
• Long-term thematic exposure is better expressed through diversified beneficiaries of rising power demand (e.g., utilities, grid, electrical equipment) rather than a single pre-revenue reactor developer.
• Monitor for a pair trade opportunity: long a broader power-demand beneficiary basket, short SMR on rallies if no commercialization milestone emerges within 1-2 quarters; this captures the theme without taking single-name execution risk.